AYER, Mass.--(BUSINESS WIRE)--Cambrooke Therapeutics Inc., an innovation leader in therapeutic nutrition for inborn errors of metabolism and ketogenic diet therapy, announces the introduction of two new low-meat alternatives protein foods: Burger Patty and Chicken Patty Dry Mixes.
Both the Cambrooke’s Burger Patty and Chicken Patty Mixes are deliciously seasoned and perfect for making meat alternative patties. They can also be used for other recipes such as tacos, stuffed peppers, meatballs, chili and more. Cambrooke’s Burger Patty Mix has 0.6g of protein and 21 mg of phe per ¼ cup (28 grams) and the Chicken Patty Mix has 0.5g of protein and 18 mg of phe per ¼ cup (35 grams) per serving.
Cambrooke’s Burger Patty and Chicken Patty Mixes contain only natural ingredients and flavors. Both come in convenient, resealable 1.5lb packages and are easily prepared just by mixing with water. Cambrooke’s Founder and Vice president of Food Innovation Lynn Paolella said, “While talking to parents and kids throughout the summer at camps and meetings, we learned that this product was in high demand. We immediately started to develop something that would not only taste great but also be nutritious. I enjoy cooking, talking with PKU patients and caregivers, and being able to continually innovate to meet the needs of PKU families. That is the heart of Cambrooke’s mission.”
JoAnn, mother of an eight-year-old daughter with PKU, said, “I was talking to Lynn about meat alternative mixes just three short months ago in Indianapolis. To see it come to fruition so quickly is unbelievable. The texture and versatility of the patty mix is amazing. My entire family is excited about both products, and we look forward to traveling with these new food options during our upcoming holiday vacation.”
About Cambrooke Therapeutics – Founded in 2000, Cambrooke Therapeutics is a private equity-backed, Massachusetts-based therapeutic nutrition company and global provider of medical nutrition products for patients with serious unmet medical needs. The company works with physicians and researchers from around the world to develop, test and commercialize products that are focused on inborn errors of metabolism and intractable epilepsy. More information is available at www.cambrooketherapeutics.com
